SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that its Board of Directors has unanimously adopted a limited duration stockholder rights agreement (the “Rights Agreement”) to protect stockholder interests.

加利福尼亚州南旧金山，2025年3月13日（环球新闻社）——Pliant Therapeutics公司（纳斯达克股票代码：PLRX）今日宣布其董事会一致通过了一项有限期限的股东权利协议（“权利协议”），以保护股东利益。

The Board resolved to adopt the Rights Agreement in response to recent accumulations of the Company’s common stock. The Rights Agreement is intended to reduce the likelihood that any entity, person or group is able to gain control of Pliant through open market accumulation without paying all stockholders an appropriate control premium or providing the Board sufficient opportunity to make informed judgments and take actions that are in the best interests of all stockholders..

董事会决定采纳权利协议，以应对近期公司普通股的积累情况。权利协议旨在降低任何实体、个人或团体通过公开市场积累获得Pliant控制权的可能性，而无需向所有股东支付适当的控制溢价，或给予董事会充分的机会作出知情判断并采取符合所有股东最佳利益的行动。

Pursuant to the Rights Plan, Pliant will issue, by means of a dividend, one preferred share purchase right for each outstanding share of Pliant common stock to stockholders of record on the close of business on March 25, 2025. Initially, these rights will not be exercisable and will trade with, and be represented by, the shares of Pliant common stock..

根据权利计划，Pliant 将通过股息的方式，向截至 2025 年 3 月 25 日营业结束时在册的股东，就每一股已发行的 Pliant 普通股发放一份优先股购买权。最初，这些权利不可行使，并将随附于 Pliant 普通股股票一同交易且由其代表。

The Rights Agreement will expire on March 11, 2026, or earlier, as provided in the Rights Agreement.

权利协议将于2026年3月11日或权利协议中规定的更早日期到期。

The terms of the Rights Agreement are consistent with other rights plans adopted by publicly-held companies. Under the Rights Agreement, the rights generally become exercisable if a person or a group of persons (each, an “acquiring person”) acquires beneficial ownership of 10% (or 20% in the case of certain investors filing on Schedule 13G) or more of the outstanding shares of Pliant common stock in a transaction not approved by the Board.

权利协议的条款与其他公开上市公司的权利计划一致。根据权利协议，如果个人或一群人（每个“收购人”）在未经董事会批准的交易中获得了Pliant普通股已发行股份的10%（或某些根据13G表格申报的投资者为20%）或更多的受益所有权，权利通常便可行使。

In that situation, each holder of a right (other than the acquiring person, whose rights will become void and will not be exercisable) will be entitled to purchase, at the then-current exercise price, additional shares of Pliant common stock at a 50% discount. In addition, if Pliant is acquired in a merger or other business combination after an unapproved party acquires 10% (or 20% in the case of certain investors filing on Schedule 13G) or more of the outstanding shares of Pliant common stock, each holder of a right would then be entitled to purchase, at the then-current exercise price, shares of the acquiring company’s stock at a 50% discount.

在这种情况下，每位权利持有人（收购方的权利将失效且不可行使）将有权按当时行权价格的五折购买更多的Pliant普通股。此外，如果Pliant在未经批准的一方收购其10%（或对于某些根据13G表申报的投资者为20%）或更多已发行普通股后，通过合并或其他业务组合被收购，那么每位权利持有人将有权按当时行权价格的五折购买收购公司的股票。

The Board, at its option, may exchange each right (other than rights owned by the acquiring person that have become void) in whole or in part, at an exchange ratio of one share of Pliant common stock per outstanding right, subject to adjustment. Except as provided in the Rights Agreement, the Board is entitled to redeem the rights at $0.001 per right..

董事会可自行决定将每一权利（收购人所拥有的已失效权利除外）全部或部分交换，交换比率为每股Pliant普通股对应每项未偿权利，此比率可进行调整。除非权利协议另有规定，董事会有权以每项权利0.001美元的价格赎回权利。

If a person or group beneficially owns 10% (or 20% in the case of certain investors filing on Schedule 13G) or more of the outstanding shares of Pliant common stock prior to Pliant’s announcement of its adoption of the Rights Agreement, then that person’s or group’s existing ownership percentage will be grandfathered (except that, with certain exceptions, if at any time after the announcement of the adoption of the Rights Agreement such person or group increases its ownership of Pliant common stock, such person’s or group’s ownership percentage will no longer be considered grandfathered)..

如果某个人或集团在Pliant宣布采纳权利协议之前，实益拥有Pliant普通股已发行股份的10%（或在某些投资者根据Schedule 13G文件申报的情况下为20%）或更多，则该个人或集团现有的持股比例将被“祖父条款”豁免（但存在某些例外情况，即如果在宣布采纳权利协议之后的任何时候，该个人或集团增加了其对Pliant普通股的持股比例，则该个人或集团的持股比例将不再被视为符合‘祖父条款’豁免）。

Additional information regarding the Rights Agreement will be contained in a current report on Form 8-K to be filed by Pliant with the U.S. Securities and Exchange Commission.

有关权利协议的更多信息将包含在Pliant向美国证券交易委员会提交的8-K表格的当前报告中。

Sidley Austin LLP is acting as legal counsel to Pliant.

西德利·奥斯汀律师事务所（Sidley Austin LLP）担任Pliant的法律顾问。

About Pliant Therapeutics, Inc.

关于Pliant Therapeutics公司。

Pliant Therapeutics is a late-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. Pliant's lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of α

Pliant Therapeutics是一家处于后期阶段的生物制药公司，也是发现和开发用于治疗纤维化疾病新疗法的领军者。Pliant的主要候选产品bexotegrast（PLN-74809）是一种口服的小分子，双重选择性α抑制剂。

v

v

ß6 and α

ß6 和 α

v

v

ß

ß

1

1

integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or IPF. Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and Orphan Drug Designation from the European Medicines Agency in IPF.

正在开发的适应症为特发性肺纤维化（IPF）治疗的整合素。Bexotegrast 已获得美国食品药品监督管理局（FDA）的快速通道资格和孤儿药资格，并且还获得了欧洲药品管理局在 IPF 领域的孤儿药资格。

Pliant is conducting a Phase 1 study of PLN-101095, a small molecule, dual-selective inhibitor of α.

Pliant 正在进行 PLN-101095 的 1 期研究，PLN-101095 是一种小分子、双重选择性 α 抑制剂。

v

v

ß

ß

8

8

and α

和 α

v

v

ß

ß

1

1

integrins, that is being developed for the treatment of solid tumors. In addition, Pliant has received regulatory clearance for the conduct of a Phase 1 study of PLN-101325, a monoclonal antibody agonist of integrin α

整合素，正在开发用于治疗实体瘤。此外，Pliant 已获得监管批准，可以进行 PLN-101325 的 1 期研究，PLN-101325 是一种整合素 α 的单克隆抗体激动剂。

7

7

β

β

1

1

targeting muscular dystrophies.

针对肌肉萎缩症。

Investor and Media Contact:

投资者和媒体联系人：

Christopher Keenan

克里斯托弗·基南

Vice President, Investor Relations and Corporate Communications

副总裁，投资者关系和企业传播

Pliant Therapeutics, Inc.

可塑性治疗公司

ir@pliantrx.com

ir@pliantrx.com